Author Archives: admin


Stem Cell Clinic > Articles by: admin

Duke Health System CEO appointed to head Institute of Medicine – Boston.com

By Uncategorized

Duke University Health SystemDr. Victor J. Dzau, the current president and CEO of Duke University Health System

Dr. Victor J. Dzau, the current president and CEO of Duke University Health System and chancellor for health affairs at Duke University, has been appointed to a six-year term as the next president of the Institute of Medicine (IOM), effective July 1, 2014. Dr. Dzau will take over the lead role from Dr. Harvey Fineberg, who served in the position for twelve years.

Dr. Dzau began his career in medicine as a cardiologist, having previously taught at Harvard Medical School and served as chair of the department of medicine. He also worked at Brigham and Womens Hospital as the director of research. His ongoing award-winning research has been key in the development of cardiovascular drugs, as well as techniques to repair tissue damage from heart attacks and heart disease using stem cell therapies.

Dr. Eugene Braunwald, often called the father of modern cardiology and a professor of medicine at Harvard Medical School, has known Dr. Dzau for more than 40 years and worked with him at many different stages of his career at Brigham and Womens Hospital and Partners Healthcare. In an interview Wednesday he called the upcoming IOM president a force of nature.

He is what I would call a talented, quadruple threat. A great physician, inspiring teacher, and a very creative scientist, said Dr. Braunwald, who trained Dzau when he was a resident at Brigham and Womens and continued to work with him on cardiovascular research when Dr. Dzau became chief resident, and then faculty at Harvard Medical School. The quadruple threat is that he also sees the larger picture. Hes interested in areas of medicine that most academic physicians have stayed away from. His work and ideas in global and community-based medicine have left an important heritage at each institution where hes worked.

After nearly a decade at Duke, Dr. Dzaus leadership has been credited with the launch of a number of innovative and global-focused medical institutions, including the Duke-National University of Signapore Graduate Medical School, Duke Global Health Institute, Duke Institute for Health Innovation, Duke Cancer Institute, as well as the Duke Translational Medicine Institute.

Im deeply honored to become the next president of the IOM and recognize the critically important role that the IOM will have in improving the health of the nation at a time of extraordinary evolution in biomedical research and health care delivery, Dzau said in a press release from Duke University Health System. The explosion of new data resources, novel technologies and breathtaking research advances make this the most promising time in history for driving innovations that will improve health care delivery, outcomes and quality.

As the health sciences extension of the National Academy of Sciences, the Institute of Medicine is known for its leadership in advancing health sciences and objective medical research nationally as a nonprofit academic research organization. The outgoing IOM president, Dr. Harvey Fineberg (previously Dean of the Harvard School of Public Health) has lead the nonprofit for twelve years. His focus and research have centered around public health policy and an improvement in informed medical decision making.

This leaves the medical community wondering what Dr. Dzau will bring to the Institute.

As a former chairman of the Association of Academic Health Centers (AAHC), Dr. Dzau advocated for the innovative transition of academic medical and health centers into institutions that can survive the rapid transitions in the health care industry. In a recent article in the New England Journal of Medicine, Dr. Dzau discusses the uncertain future of academic medical centers. He argues that industry pressures and cost restraints from the Affordable Care Act limit the research and education-based missions of teaching hospitals.

Here is the original post:
Duke Health System CEO appointed to head Institute of Medicine - Boston.com

'Largest ever' trial of adult stem cells in heart attack patients begins

By Stem Cell Doctors

Current ratings for: 'Largest ever' trial of adult stem cells in heart attack patients begins

Public / Patient:

5 1 rating

Health Professionals:

0 0 ratings

The largest ever trial of adult stem cell therapy in heart attack patients has begun at The London Chest Hospital in the UK.

Heart disease is the world's leading cause of death. Globally, more than 17 million people died from heart disease last year. In the US, over 1 million people suffer a heart attack each year, and about half of them die.

Heart attacks are usually caused by a clot in the coronary artery, which stops the supply of blood and oxygen to the heart. If the blockage is not treated within a few hours, then it causes the heart muscle to die.

The stem cell trial - titled "The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on allcause mortality in acute myocardial infarction," or "BAMI" for short - has been made possible due to a 5.9 million ($8.1 million) award from the European Commission.

The full study involves 19 partners across France, Germany, Italy, Finland, Denmark, Spain, Belgium, Poland, the Czech Republic and the UK.

Read this article:
'Largest ever' trial of adult stem cells in heart attack patients begins

This week in health: Prostate cancer and stem cell breakthroughs, snoozing and headaches

By Stem Cell Medicine

Canada.com Health takes a look at a few stories you may have missed this week.

A new study may suggest a re-think is in order in the way we treat prostate cancer. Dr. Julia Hayes, at the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute, led a study that has found observation to be a reasonable alternative to initial treatment for the 70 percent of men who are diagnosed with low-risk prostate cancer.

Related:

At the same time, research continues at Dana-Farber to identify additional biomarkers that can aid in the diagnosis of prostate cancer, as well as to find genetic abnormalities in prostate cancer cells that might indicate how they would respond to certain treatments.

More information on the study can be found here.

PHOTO: Stringer/AFP/Getty Images A scientist conducts research on stem cells at a laboratory in Bangalore, India.

A new study shows it may be possible to reverse aging in muscles.

Researchers at the Stanford University School of Medicine have discovered a possible explanation for why muscles take longer to heal in older bodies: the stem cells within muscle tissues that are supposed to repair damage become less able over time to generate new fibres and self-renew.

Related:

But the research team, led by Dr. Helen Blau, also claim to have discovered a way to rejuvenate these older muscle stem cells so that they function like younger cells. The results of their study has been published in Nature Medicine.

Read more:
This week in health: Prostate cancer and stem cell breakthroughs, snoozing and headaches

Stem Cells from Fat Tissue Show Promise in Reconstructive Surgeries for Face and Skull

By Stem Cell Medicine

Durham, NC (PRWEB) February 21, 2014

A new study released today in STEM CELLS Translational Medicine shows that many patients with defects to the skull, face or jaw bone might benefit from reconstructive surgery combining stem cells taken from adipose (fat) tissue seeded on resorbable scaffolds.

These defects can be due to congenital malformations, such as cleft lip and palate, or to traumatic injuries or surgery to remove a tumor. The use of a patients own bone is still considered the gold standard for reconstructing these defects, but this requires yet another surgery to harvest the bone for the reconstructive procedure. The STEM CELLS Translational Medicine study tracked the case of 13 patients undergoing regenerative medicine procedures.

To our knowledge, this study represents the first GMP-compliant application for autologous adipose-derived stem cells in the treatment of defects at various sites of the cranio-maxillofacial skeleton, said the studys lead investigator, George K. Sndor, M.D., DDS, Ph.D., of the University of Tampere (UT), Tampere, Finland. He and Susanna Miettinen, Ph.D., were lead investigators on the study conducted by scientists and clinicians who, in addition to UT, came from the University of Oulu (Oulu, Finland) and Central Hospital (Jyvskyl, Finland).

Isolated reports of hard tissue (bone) reconstruction in the skull, face or jaw (cranio-maxillofacial skeleton) exist, but multi-patient case series are lacking. This study aimed to review the experience of 13 people with hard tissue defects at four anatomically different sites: the frontal sinus (three cases), cranial bone (five cases), the jaw (three cases) and the nasal septum (two cases).

Stem cells were harvested from adipose tissue in each patients abdomen, treated in the lab and then seeded onto resorbable scaffold materials for implantation back into the patient. The scaffolds were constructed with either bioactive glass or -TCP (a bone graft substitute). In some cases a protein called rhBMP-2, which plays an important role in the development of bone and cartilage, was added, too.

The results were promising. All three of the frontal sinus cases and three of the five cranial defect cases were successfully treated. (The other two cranial cases in which non-rigid resorbable containment meshes were used sustained bone resorption to the point that they required a redo procedure.) One of the two septal perforations failed after a year due to an infection resulting from the patients own actions, but the other healed successfully.

The three patients with reconstructed jaw defects also had good results; in fact, two of them chose to have dental implants placed directly into the stem cell-seeded grafts after healing, allowing these patients to once again enjoy a normal diet.

While the resorption of some of the constructs in the cranial defects was more than expected, Nevertheless, Dr. Sndor said, the majority of these challenging defects 10 of 13 were successfully treated with integration of the stem cell-seeded constructs to the surrounding skeleton at the defect sites. Dr. Miettinen added that the next steps should involve more animal studies and tracking of long-term results in humans.

This case series, involving various sites of defect, illustrates the potential promise of engineering replacement bone in the lab to avoid harvesting bone from the patient, commented Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

See the original post:
Stem Cells from Fat Tissue Show Promise in Reconstructive Surgeries for Face and Skull

Stem cell donor clinic planned for 4-year-old battling leukemia again

By Stem Cell Treatment

Paul Herron and Anne Hodgkinson wake up every day knowing their daughter could die.

Their 4-year-old, Katie, has cancer, and for the second time in her young life she is fighting to stay alive.

Shes scared. Shes terrified, Herron told the Star from Torontos Ronald McDonald House, where the Cambridge family is currently staying so Katie can get treatment at the Hospital for Sick Children.

For Anne and I, its been a parents worst nightmare.

When Katie was just 15 months old, she was diagnosed with acute lymphoblastic leukemia. But after 25 months of intensive treatment, including lumbar punctures, bone marrow aspirations, chemotherapy and steroids, Katie fought the cancer into remission.

Finally, the family thought, they could say goodbye to hospital beds and the hours spent pacing hallways waiting for results. Finally, they could be normal.

But last November, the life they had built for themselves crumbled once again. The cancer was back, and this time Katie would need a stem cell donor.

The first time, we never made it public. We kept to ourselves, said Herron. But because this time she needs a stem cell donation, we had to get the word out.

No one in the family is a match, and the national registry has yet to turn up a name. This Saturday, Katies supporters will host a stem cell donor clinic at the Cambridge Sports Park from 1 to 5 p.m. All thats required for testing is a cheek swab.

(Stem cells are collected from a matching donors bone marrow or blood after the donor has given informed consent and undergone medical tests to encourage good health and compatibility.)

More here:
Stem cell donor clinic planned for 4-year-old battling leukemia again

THOUGHT OF THE DAY :

By Stem Cell Treatment

The biggest ever stem cell trial involving heart attack patients has got under way in London. The study, which will involve 3,000 patients in 11 European countries, should show whether the treatment can cut death rates and repair damaged tissue after a heart attack.

All the patients will have standard treatment to widen their narrowed arteries, which involves inserting a small tube called a stent. In addition, half the patients will have stem cells taken from their bone marrow and injected into their heart.

This will happen within days of them suffering a heart attack.

"It's fantastic to be part of this," said Neal Grainger, 54, from Essex, who was the first patient in the UK to be treated.

UK's biggest killer

He had an infusion of his bone marrow stem cells at the London Chest Hospital just days after his heart attack last month.

"It's strange having something taken out of you and then put back, but I hope it helps me and a lot of others."

Cardiovascular disease is the biggest killer in the UK.

During a heart attack, a fatty plaque causes a blood clot inside an artery, starving heart muscle of oxygen and leaving scar tissue.

Although more and more patients are surviving heart attacks, they can be left considerably weaker because heart muscle has been permanently damaged.

More:
THOUGHT OF THE DAY :

Stem cell donor sought for 4-year-old cancer patient

By Stem Cell Treatment

A stem cell donor clinic for four-year-old Katie Herron will be held Feb. 22, 2014 at the Cambridge Sports Centre. FACEBOOK/Katie's Kure

Four-year-old Katie Herron needs a stem cell donation to save her life. Her family hopes to find that donor at a clinic being held this Saturday.

Katie is battling acute lymphoblastic leukemia and no one in her family or the national stem cell registry has been a match so far.

Her parents Anne Hodgkinson and Paul Herron, along with an army of volunteers, are hosting a donor clinic at the Cambridge Sports Park, located at 1001 Franklin Blvd., from 1 p.m.-5 p.m. on Saturday.

Click here for the Facebook page with more information.

Men and women between the ages of 17-35 can qualify to donate stem cells. The test is a simple cheek swab, and, if its a match, a blood or bone marrow sample will later be extracted.

Anyone over 35 wishing to contribute is encouraged to donate blood, as patients waiting for transplants require frequent blood transfusions, according to the events Facebook page.

This is the little girls second time dealing with a battery of tests, treatments and hospital stays. She was first diagnosed at fifteen months, but Katie fought the cancer into remission.

Then last November, just after starting junior kindergarten, the cancer returned.

Though the type of cancer young Katie is facing often responds well to standard treatment, Katie is one of the unlucky children for whom that is not the case.

The rest is here:
Stem cell donor sought for 4-year-old cancer patient

$5B initiative proposed for stem cell research

By Stem Cell Medicine

Supporters of Californias multibillion-dollar stem cell program plan to ask for $5 billion more to bring the fruits of research to patients.

Robert Klein, a leader of the 2004 initiative campaign that established the program, said Thursday hes going to be talking with California voters about the proposal. If the public seems receptive, backers will work to get an initiative on the 2016 ballot to extend funding for the California Institute for Regenerative Medicine

Klein outlined the proposal Thursday at UC San Diego Moores Cancer Center, during a symposium on how to speed research to patient care.

Since cancer cells and stem cells share some underlying characteristics, CIRM has funded research into those similarities, including the work of Moores Cancer Center researchers David Cheresh and Catriona Jamieson.

Klein said supporters, including researchers, patients and patient advocates need to educate the public about the benefits of funding stem cell research, and the results to date. A former chairman of CIRM, Klein is no longer formally affiliated with the agency but continues to support its work.

No stem cell treatments funded by CIRM have been approved, but patients have benefited in other ways. CIRM-funded research into cancer stem cells led to a clinical trial of a drug that caused remission of a bone marrow cancer in Sandra Dillon, a patient of Jamiesons. Moreover, California has vaulted into prominence in regenerative medicine, and the field has also provided a new growth engine for the states large biotech industry.

Though CIRM has been praised for advancing quality research, it has been criticized for being slow to fund commercialization by life science companies.

In addition, CIRM has been criticized for a lack of transparency and conflicts of interest in how it awards grants. The agency revamped its policies last year to forbid members of its governing oversight committee from voting on proposals to fund research at their own institutions.

California voters set aside $3 billion in bond money for CIRM in 2004 under Proposition 71. The money is expected to run out around 2017, so Klein and other supporters have been preparing to go back to the public. The amount paid back will be $6 billion, including interest over the life of the bonds, Klein noted. So the $5 billion for CIRM would require a $10 billion bond measure.

Can it be done again? Klein asked. If we continue to have the extraordinary results the scientists and research institutes are presenting, as well as the biotech sector.

Read the rest here:
$5B initiative proposed for stem cell research

→←